RT Journal Article SR Electronic T1 Effect of anti-PcrV antibody in a murine chronic airway Pseudomonas aeruginosa infection model JF European Respiratory Journal JO Eur Respir J FD European Respiratory Society SP 965 OP 968 DO 10.1183/09031936.00147406 VO 29 IS 5 A1 Y. Imamura A1 K. Yanagihara A1 Y. Fukuda A1 Y. Kaneko A1 M. Seki A1 K. Izumikawa A1 Y. Miyazaki A1 Y. Hirakata A1 T. Sawa A1 J. P. Wiener-Kronish A1 S. Kohno YR 2007 UL http://erj.ersjournals.com/content/29/5/965.abstract AB Pseudomonas aeruginosa is one of the most important pathogens in patients with chronic airway conditions, such as cystic fibrosis and diffuse panbronchiolitis. Type III secretion system-mediated virulence factors contribute to the lung damage in chronic P. aeruginosa infection. The effects of the anti-PcrV immunoglobulin (Ig)G, which blocks the type III secretion system, were evaluated in a mouse model of chronic P. aeruginosa infection. On bacteriological examination, anti-PcrV IgG showed no bactericidal effects. On bronchoalveolar lavage fluid (BALF) analysis, total cell number and neutrophil ratios in the anti-PcrV IgG-treated groups were lower than those in the control group. In addition, macrophage inflammatory protein-2, tumour necrosis factor-α, and interleukin-β concentrations in BALF were lower in the anti-PcrV IgG-treated groups when compared with controls. Plasma anti-PcrV IgG titre was elevated after administration of anti-PcrV IgG. Although plasma titre decreased gradually, a significant concentration was maintained during the experimental period. These data suggest that anti-PcrV immunoglobulin G reduces the inflammatory reaction caused by chronic Pseudomonas aeruginosa respiratory infection and may be useful in treating respiratory diseases.